A phase II/III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms OLYMPUS
- Sponsors Genentech
- 26 Feb 2022 Results using data from ORATORIO, OLYMPUS and ARPEGGIO; predicting the conditional average treatment effect for individuals taking anti-CD20 monoclonal antibodies and laquinimod by using deep learning, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2022
- 01 Oct 2009 Results published in Annals of Neurology.
- 12 May 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.